Healthy Inc > Blog > Levodopa BP/USP/IP
Posted on:

What is the brand name for levodopa and carbidopa combination?

In the pharmaceutical industry, the combination of Levodopa and Carbidopa is the “Gold Standard” for the management of Parkinson’s disease. As a pharmacist and manufacturer, I classify this as a dopamine precursor and decarboxylase inhibitor combination.

While Sinemet is the global innovator brand, there are several key regional and generic brands that are highly relevant for your B2B marketplace and export operations.

Primary Brand Names

RegionBrand NameManufacturer (Innovator/Major)
Global / USASinemetMerck (Innovator) / Organon
IndiaSyndopaSun Pharmaceutical Industries
IndiaLCDIntas Pharmaceuticals
IndiaTidometTorrent Pharmaceuticals
Global (Extended Release)RytaryAmneal Pharmaceuticals
Global (Intestinal Gel)DuopaAbbVie

Mechanism: The “Trojan Horse” Strategy

The reason these two are combined is a classic example of pharmacokinetic synergy. Levodopa alone is highly inefficient because it is destroyed before it reaches the brain.

Levodopa (The Precursor): Levodopa can cross the Blood-Brain Barrier (BBB). Once inside the brain, it is converted into Dopamine, restoring the levels needed for smooth muscle movement.

Carbidopa (The Protector): Carbidopa cannot cross the BBB. Its job is to stay in the bloodstream and block the enzyme DOPA Decarboxylase. This prevents Levodopa from being converted to dopamine in the body (periphery).

The Result: By protecting Levodopa in the bloodstream, Carbidopa allows more of it to reach the brain. This also significantly reduces side effects like severe nausea and vomiting caused by dopamine in the blood.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your WHO-GMP facility in Mumbai, this combination is a high-precision CNS (Central Nervous System) product:

  • The 4:1 and 10:1 Ratios: On your marketplace, you should highlight that you offer standard ratios like 100/10 mg, 100/25 mg, and 250/25 mg. Explaining these ratios to B2B buyers shows your technical manufacturing expertise.

  • Extended Release (CR) Formulations: Promoting a Controlled Release (CR) version is a major USP. It reduces “wearing-off” effects for patients, making your product more attractive to international hospital networks.

  • Stability & Moisture Sensitivity: Levodopa is sensitive to light and moisture. At our facility, we utilize Alu-Alu blister packaging to ensure a 36-month shelf life, which is essential for export to tropical Zone IVb regions.

  • Dossier Readiness: Since Parkinson’s requires lifelong treatment, we maintain full CTD/eCTD Dossiers to support your firm in bidding for long-term government health contracts and insurance tenders.

Carbidopa and Levodopa Tablets

Posted on:

What is Levodopa and Carbidopa tablet used for?

In the pharmaceutical industry, the combination of Levodopa and Carbidopa (commonly in ratios like 100/10 mg, 100/25 mg, or 250/25 mg) is the gold-standard treatment for Parkinson’s disease. As a pharmacist, I view this pairing as a classic example of “pharmacokinetic synergy”—where one drug is specifically included only to protect and enhance the delivery of the other.

Primary Clinical Uses

  • Parkinson’s Disease (Idiopathic): The primary treatment for managing motor symptoms like tremors, rigidity (muscle stiffness), and bradykinesia (slowness of movement).

  • Post-Encephalitic Parkinsonism: Used to treat parkinsonian symptoms following viral encephalitis.

  • Drug-Induced Parkinsonism: Occasionally used to manage symptoms resulting from carbon monoxide or manganese poisoning.

  • Symptomatic Improvement: It is highly effective at improving the quality of life by restoring motor control, though it does not stop the underlying neurodegeneration.

Mechanism of Action: The “Protective Delivery” Strategy

The therapeutic success of this tablet depends entirely on the interaction between these two molecules:

Levodopa (The Precursor): Parkinson’s is caused by a lack of dopamine in the brain. Since dopamine itself cannot cross the Blood-Brain Barrier (BBB), we use Levodopa, an amino acid precursor that can cross the BBB. Once inside the brain, it is converted into dopamine.

Carbidopa (The Protector): If Levodopa is taken alone, 95% of it is converted into dopamine in the bloodstream before it reaches the brain. This causes severe nausea and prevents the drug from working. Carbidopa is a peripheral dopa-decarboxylase inhibitor. It stays in the bloodstream (it cannot enter the brain) and prevents the premature conversion of Levodopa.

By adding Carbidopa, we increase the amount of Levodopa available to enter the brain by up to 80%, while simultaneously reducing the peripheral side effects like vomiting and cardiac arrhythmias.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Levodopa/Carbidopa is a high-precision CNS (Central Nervous System) product:

  • Fixed-Dose Ratio Precision: As a WHO-GMP manufacturer, we ensure the ratio (usually 4:1 or 10:1) is exact. Even minor deviations can lead to poor symptom control or increased toxicity.

  • Controlled Release (CR) Formulations: We also manufacture Sustained Release versions to provide a steady “trickle” of dopamine, which helps prevent the “on-off” phenomenon (sudden loss of drug effect) common in long-term Parkinson’s patients.

  • Oxidation Control: Levodopa is sensitive to light and air. We utilize Alu-Alu blister packaging to ensure the tablets do not darken or lose potency during export to Zone IVb regions (hot and humid) like Africa and Southeast Asia.

  • Global Export Niche: This is an essential medicine for neurology clinics and geriatric care centers worldwide. Our Mumbai facility provides full CTD/eCTD Dossier support for international B2B partners.

Carbidopa and Levodopa Tablets

Add to cart